Cell Biotech Co., Ltd. (KOSDAQ:049960)

Cell Biotech Statistics

Total Valuation

Cell Biotech has a market cap or net worth of KRW 95.95 billion. The enterprise value is 7.57 billion.

Market Cap	95.95B
Enterprise Value	7.57B

Important Dates

The last earnings date was Wednesday, November 12, 2025.

Earnings Date	Nov 12, 2025
Ex-Dividend Date	Dec 29, 2025

Share Statistics

Cell Biotech has 6.84 million shares outstanding. The number of shares has decreased by -0.04% in one year.

Current Share Class	6.84M
Shares Outstanding	6.84M
Shares Change (YoY)	-0.04%
Shares Change (QoQ)	+0.14%
Owned by Insiders (%)	35.13%
Owned by Institutions (%)	8.76%
Float	4.44M

Valuation Ratios

The trailing PE ratio is 7.62.

PE Ratio	7.62
Forward PE	n/a
PS Ratio	1.89
PB Ratio	0.75
P/TBV Ratio	0.76
P/FCF Ratio	11.44
P/OCF Ratio	8.26
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 0.78, with an EV/FCF ratio of 0.90.

EV / Earnings	0.60
EV / Sales	0.15
EV / EBITDA	0.78
EV / EBIT	1.26
EV / FCF	0.90

Financial Position

The company has a current ratio of 13.72, with a Debt / Equity ratio of 0.00.

Current Ratio	13.72
Quick Ratio	12.94
Debt / Equity	0.00
Debt / EBITDA	0.06
Debt / FCF	0.07
Interest Coverage	150.87

Financial Efficiency

Return on equity (ROE) is 10.31% and return on invested capital (ROIC) is 3.04%.

Return on Equity (ROE)	10.31%
Return on Assets (ROA)	2.90%
Return on Invested Capital (ROIC)	3.04%
Return on Capital Employed (ROCE)	4.71%
Revenue Per Employee	501.47M
Profits Per Employee	124.67M
Employee Count	101
Asset Turnover	0.39
Inventory Turnover	3.30

Taxes

Income Tax	-22.46M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +0.94% in the last 52 weeks. The beta is 0.39, so Cell Biotech's price volatility has been lower than the market average.

Beta (5Y)	0.39
52-Week Price Change	+0.94%
50-Day Moving Average	12,431.00
200-Day Moving Average	12,899.40
Relative Strength Index (RSI)	71.76
Average Volume (20 Days)	27,201

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Cell Biotech had revenue of KRW 50.65 billion and earned 12.59 billion in profits. Earnings per share was 1,840.28.

Revenue	50.65B
Gross Profit	36.48B
Operating Income	5.99B
Pretax Income	12.57B
Net Income	12.59B
EBITDA	9.65B
EBIT	5.99B
Earnings Per Share (EPS)	1,840.28

Balance Sheet

The company has 88.96 billion in cash and 577.11 million in debt, giving a net cash position of 88.38 billion or 12,913.79 per share.

Cash & Cash Equivalents	88.96B
Total Debt	577.11M
Net Cash	88.38B
Net Cash Per Share	12,913.79
Equity (Book Value)	127.11B
Book Value Per Share	18,575.08
Working Capital	93.72B

Cash Flow

In the last 12 months, operating cash flow was 11.62 billion and capital expenditures -3.24 billion, giving a free cash flow of 8.39 billion.

Operating Cash Flow	11.62B
Capital Expenditures	-3.24B
Free Cash Flow	8.39B
FCF Per Share	1,225.36

Margins

Gross margin is 72.03%, with operating and profit margins of 11.82% and 24.86%.

Gross Margin	72.03%
Operating Margin	11.82%
Pretax Margin	24.82%
Profit Margin	24.86%
EBITDA Margin	19.05%
EBIT Margin	11.82%
FCF Margin	16.56%

Dividends & Yields

This stock pays an annual dividend of 450.00, which amounts to a dividend yield of 3.21%.

Dividend Per Share	450.00
Dividend Yield	3.21%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	24.46%
Buyback Yield	0.04%
Shareholder Yield	3.25%
Earnings Yield	13.12%
FCF Yield	8.74%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Cell Biotech has an Altman Z-Score of 10.09 and a Piotroski F-Score of 4.

Altman Z-Score	10.09
Piotroski F-Score	4